Company code: Xiamen Amoytop Biotech Co.Ltd(688278) company abbreviation: Xiamen Amoytop Biotech Co.Ltd(688278) Xiamen Amoytop Biotech Co.Ltd(688278)
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 Unprofitable and unprofitable when the company is listed □ yes √ no III. tips on major risks
The company has described in detail the possible risks and Countermeasures in the business process in this report. Please refer to "IV. risk factors" in Section III "management discussion and analysis". 4、 All directors of the company attended the board meeting. 5、 Rongcheng Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6、 Sun Li, the person in charge of the company, Yang Yiling, the person in charge of accounting, and Yang Yiling, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The company's profit distribution plan for 2021 is: Based on the total share capital on the registration date of dividends and dividends, the company plans to distribute cash dividends of RMB 1 (including tax) to all shareholders for every 10 shares, without converting capital reserve into share capital and bonus shares. As of December 31, 2021, the total share capital of the company is 406800000 shares. Based on this calculation, the total cash dividend to be distributed is 40680000 yuan (including tax). The above profit distribution plan has been deliberated and approved at the sixth meeting of the eighth board of directors of the company, and can be implemented only after it is submitted to the general meeting of shareholders for deliberation and approval. 8、 Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable IX. risk statement of forward-looking statements √ applicable □ not applicable
The company's future plans, development strategies and other forward-looking descriptions involved in this report do not constitute the company's substantive commitment to investors. Please pay attention to investment risks. 10、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties? Xi. Whether there is any external guarantee in violation of the specified decision-making procedures? No
12、 Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the annual report disclosed by the company no XIII. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 47 Section V environment, social responsibility and other corporate governance Section 6 important matters Section VII share changes and shareholders 119 Section VIII preferred shares Section 9 relevant information of corporate bonds 129 section x financial report one hundred and thirty
Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor)
The catalogue of documents for future reference contains the original audit report sealed by the accounting firm and signed and sealed by the certified public accountant
Originals of all company documents and announcements publicly disclosed during the reporting period
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company, the company, Xiamen Amoytop Biotech Co.Ltd(688278) , Tebao refers to Xiamen Amoytop Biotech Co.Ltd(688278)
department
Bosai and bosai gene refer to Xiamen bosai gene transcription Technology Co., Ltd., a wholly-owned subsidiary of the company
Tonghua Dongbao Pharmaceutical Co.Ltd(600867) refers to Tonghua Dongbao Pharmaceutical Co.Ltd(600867)
Certified Public Accountants and Rongcheng Certified Public Accountants (special general partnership)
Securities Law refers to the securities law of the people's Republic of China
Articles of association means Xiamen Amoytop Biotech Co.Ltd(688278) articles of association
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
The reporting period refers to 2021
A class of soluble polypeptides, which are produced by a variety of cells in the human body and can act. Cytokines refer to different immune cells and hematopoietic cells. They mainly play a role in regulating the body's response, hematopoietic function and inflammatory response.
Polyethylene glycol modification, also known as molecular PEGylation, couples activated polyethylene glycol with protein molecules, affects the spatial structure of protein polyethylene glycol modification, and finally leads to changes in various biochemical properties of protein: increased chemical stability, The ability to resist protease hydrolysis is improved, the immunogenicity is reduced, the half-life in vivo is prolonged, and the plasma clearance rate is reduced.
Modification site refers to the position of amino acids chemically linked or changed by specific chemical groups.
It refers to the synthesis of drugs before entering the clinical research, including the research on process, extraction method, physical and chemical properties and purity, dosage form selection, prescription screening, preparation process, test method, quality index, stability, pharmacology, toxicology, animal pharmacokinetics, etc.
A stage of drug research and development, generally refers to the stage from obtaining clinical research approval, clinical research and clinical trial to completing phase I, II and III clinical trials and obtaining clinical research summary report.
A kind of clinical trial, the purpose of which is to confirm the effectiveness and safety of confirmatory clinical research, provide the basis for evaluating the benefit / risk relationship to support registration, and determine the relationship between dose and effect.
National Class 1 new drugs for biological products refer to new drugs registered and classified as class 1 biological products for treatment.
Innovative drugs refer to drugs whose chemical structure, drug components and pharmacological effects are different from existing drugs, or drugs that have not been listed and sold in China or abroad.
Chronic hepatitis B (chronic hepatitis B), chronic hepatitis C, chronic hepatitis B and chronic hepatitis B; Chronic chronic hepatitis C (chronic hepatitis C) is a chronic necrotizing inflammation caused by hepatitis B virus hepatitis, chronic hepatitis C (hepatitis B virus) and hepatitis C virus (HCV) infection.
Viral hepatitis is caused by a variety of hepatitis viruses, mainly liver damage. Viral hepatitis refers to a group of systemic infectious diseases. At present, according to the etiology, there are five hepatitis viruses: type A, type B, type C, type D and type E.
It is made of ordinary interferon modified by polyethylene glycol molecule. Compared with ordinary polyethylene glycol interferon, it refers to the advantages of interferon with larger molecular weight, lower renal clearance, lower immunogenicity, more stable blood concentration, lower administration frequency and better curative effect.
Pegylated interferon refers to the generic name of the drug pegylated interferon α- 2B injection is a long-acting interferon product produced by the company.
Combination therapy is a combination of nucleoside and long-acting interferon for chronic hepatitis B antiviral treatment.
A series of active proteins that can regulate hematopoietic stem / progenitor cell survival, proliferation, differentiation and hematopoietic growth factors refer to the functions of mature blood cells. They are mainly composed of colony stimulating factors (CSF) and interleukin (ILS), most of which are related to immune related functions.
Selective granulocyte stimulating factor (G-CSF) is one of the main cytokines regulating granulopoiesis in bone marrow. It acts on granulopoietic progenitor cells, promotes their proliferation and differentiation, and can increase the function of granulocyte terminal differentiated cells.
Recombinant human granulocyte stimulating factor (rhG - refers to the recombinant human granulocyte stimulating factor CSF) drug prepared by genetic engineering technology.
Y-type polyethylene glycol recombinant human granulocyte stimulating factor is a long-acting recombinant human granulocyte stimulating factor drug that uses 40KD Y-type branched polyethylene glycol (PEG) molecule to modify recombinant human daughter (yg-g-csf) finger granulocyte stimulating factor (rhG CSF).
The invention relates to a hematopoietic growth factor that acts on hematopoietic progenitor cells, promotes their proliferation and differentiation, induces granulocyte macrophage stimulating factor (GM refers to granulocyte and monocyte macrophage mature and released to peripheral blood, and can CSF) and promotes the multiple functions of macrophages and eosinophils.
Recombinant human granulocyte macrophage stimulating factor refers to the recombinant human granulocyte macrophage stimulating factor (rhGM CSF) drug prepared by genetic engineering technology.
A sectorlet growth promoting factor, which can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induce megakaryocytes (capable of producing blood)
